Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Global anti-rheumatics revenue of top pharmaceutical companies 2017 and 2024

This statistic shows the top ten pharmaceuticals companies worldwide based on anti-rheumatics revenue in 2017 and a projection for 2024. In 2017, Pfizer generated some six billion U.S. dollars in anti-rheumatics revenue and is expected to generate around the same revenue by 2022. Anti-rheumatic drugs are used to treat and slow the progress of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that principally attacks the joints but also impacts tissues and organs.

Top 10 pharmaceutical companies based on global anti-rheumatics revenue in 2017 and 2024

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until May 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

June 2018

Region

Worldwide

Survey time period

as of May 2018

Supplementary notes

* Projected.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pharmaceutical industry in Scandinavia "

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.